 MIAMI, July 7, 2021 PRNewswire -- Big Cypress Acquisition Corp. NASDAQ: BCYP, Big Cypress a blank check company focused on innovative biopharmaceutical firms, today announced the confidential submission with the U.S. Securities and Exchange Commission SEC of a draft registration statement on Form S-4 the Registration Statement relating to its previously announced proposed business combination with SAB Biotherapeutics, Inc. SAB, a clinical-stage biopharmaceutical company that is developing a novel immunotherapy platform producing targeted, high potency, fully-human polyclonal antibody therapeutics and advancing programs in infectious disease, immune system disorders and oncology. Submitting the draft S-4 registration statement marks another milestone on our path to successfully completing our planned merger with SAB Biotherapeutics, said Samuel J. 